Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors

Deeken, John F.; Shimkus, B.; Liem, André; Hill, David P.; Gurtler, Jayne S.; Berghorn, Elmer; Townes, L.; Lu, Haolan; Trifan, Ovidiu C.; Zhang, S.

doi:10.1007/s00280-013-2146-5

Cited by 15 publications

(10 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with the literature regarding cetuximab administration for therapeutic purposes, a small increase of QTc interval was seen after infusion of the loading dose cetuximab with no further increase after cetuximab-IRDye800. 19,20 QTc interval gradually decreased to baseline and none of the patients had persistent increased QTc after the observation period.…”

Section: Resultsmentioning

confidence: 93%

Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging

et al. 2018

View full text Add to dashboard Cite

Background Operative management of pancreatic ductal adenocarcinoma (PDAC) is complicated by several key decisions during the procedure. Identification of metastatic disease at the outset and, when none is found, complete (R0) resection of primary tumor are key to optimizing clinical outcomes. The use of tumor-targeted molecular imaging, based on photoacoustic and fluorescence optical imaging, can provide crucial information to the surgeon. The first-in-human use of multimodality molecular imaging for intraoperative detection of pancreatic cancer is reported using cetuximab-IRDye800, a near-infrared fluorescent agent that binds to epidermal growth factor receptor. Methods A dose-escalation study was performed to assess safety and feasibility of targeting and identifying PDAC in a tumor-specific manner using cetuximab-IRDye800 in patients undergoing surgical resection for pancreatic cancer. Patients received a loading dose of 100 mg of unlabeled cetuximab before infusion of cetuximab-IRDye800 (50 mg or 100 mg). Multi-instrument fluorescence imaging was performed throughout the surgery in addition to fluorescence and photoacoustic imaging ex vivo. Results Seven patients with resectable pancreatic masses suspected to be PDAC were enrolled in this study. Fluorescence imaging successfully identified tumor with a significantly higher mean fluorescence intensity in the tumor (0.09 ± 0.06) versus surrounding normal pancreatic tissue (0.02 ± 0.01), and pancreatitis (0.04 ± 0.01; p < 0.001), with a sensitivity of 96.1% and specificity of 67.0%. The mean photoacoustic signal in the tumor site was 3.7-fold higher than surrounding tissue. Conclusions The safety and feasibilty of intraoperative, tumor-specific detection of PDAC using cetuximab-IRDye800 with multimodal molecular imaging of the primary tumor and metastases was demonstrated.

show abstract

Section: Resultsmentioning

confidence: 93%

Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In the dosages ranging from 7.5 to 75 mg/kg in rhesus monkeys studies, Erbitux injection did not cause severe side-effects 7,8 . As reported by researches on Erbitux or its biosimilars, they reported that Erbitux did not cause vital organs pathological alterations, except rarely reported heart associated heart failure and increased heart beating rate 9 .…”

Section: ■ Discussionmentioning

confidence: 85%

Comparative safety assessments of the biosimilar APZ001 and Erbitux in pre-clinical animal models

Wang¹,

Guo²,

Deng³

et al. 2018

Acta Cir. Bras.

View full text Add to dashboard Cite

show abstract

“…Through the adverse event reporting, the clinical trials did not manage to establish a relationship between the two. The only prospective clinical study [ 60 ] identified in the literature with this primary objective was performed in 20 centers in USA, on 51 patients treated with Cetuximab for advanced H&N, NSCLC, CRC and other cancers, treated with Cetuximab monotherapy. Serial ECG monitoring was performed and also dosing of seric Cetuximab concentration; from all patients, 37 were included in the final analyses.…”

Section: Cardiovascular (Cv) Side Effects Of Cetuximabmentioning

confidence: 99%

Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab

Gherman

Căinap

Constantin

et al. 2017

Medicine and Pharmacy Reports

View full text Add to dashboard Cite

Novel emerging therapies have changed paradigms in metastatic colorectal cancer. The advantages of molecular targeted treatments, either the anti-angiogenic or the anti-epidermal growth factor receptor drugs, reside in the fact that while their specificity for the cancer cell is higher, their toxicity on normal tissues is significantly lower when compared to chemotherapy. But when it comes to their safety, especially from a cardiovascular point of view, they still need to pass the test of time and further prospective studies are needed. Clinical trial patients are very well selected with regards to comorbidities and therefore, they often differ from real-life patients. In order to maximize the benefits from these drugs, we need to better identify the population at risk, understand and early diagnose their on- and off-target adverse effects and to adequately choose the diagnostic tools; with a better prevention and early treatment, the quality and quantity of our patients’ lives can be significantly improved.

show abstract

Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors

Abstract: These results suggest that cetuximab can be safely administered as a single agent without risk of effect on QTc interval.

Cited by 15 publications

References 25 publications

Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging

Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging

Comparative safety assessments of the biosimilar APZ001 and Erbitux in pre-clinical animal models

Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab

Contact Info

Product

Resources

About